Viking Therapeutics Earnings: Q3 Maintenance Study Data A Potential Wildcard
Viking Therapeutics, Inc. (VKTX) is considered a hold due to limited near-term catalysts and increasing competition in the GLP-1 obesity and diabetes space, with its lead candidate VK2735 trailing larger peers. The company's Phase 3 VANQUISH trials are fully enrolled, but pivotal data are not expected until late 2027 or early 2028. An upcoming Q3 maintenance study readout could serve as a potential wildcard for the stock in the near term.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896534-viking-therapeutics-earnings-q3-maintenance-study-data-a-potential-wildcard"},"author":{"@type":"Person","name":"Edmund…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
